Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THPMarcin Kubeczko, F. Braso-Maritany, Sandra Cobo et al.|Clinical Cancer Research|2026Cited by 0
Abstract PS3-10-24: Biologic and Pathologic Correlations of the HER2DX Genomic Test in HER2+ DiseaseE. Sanfeliu, A. Prat, M. Muñoz et al.|Clinical Cancer Research|2026Cited by 0
Abstract PS5-01-08: Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THPRodrigo Sánchez-Bayona, M. Jarzab, Sandra Cobo et al.|Clinical Cancer Research|2026Cited by 0
Abstract PS4-07-06: Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancerF. Brasó-Maristany, M. Alva, E. Ciruelos et al.|Clinical Cancer Research|2026Cited by 0